Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject

Inclusion Criteria: * Participant must be informed of the nature of the study and voluntarily agree to participate by signing an informed consent form prior to any study-specific procedures. * Participant must be a healthy male, aged 18 to 70 years (inclusive) at the time of dosing. * Participant must be judged by the Investigator or designee to be in good general health, as documented by medical history, physical examination, clinical laboratory tests, vital signs, and 12-lead electrocardiogram (ECG). Any deviations from normal ranges must be assessed and deemed not clinically significant by the Investigator or designee. * Participant must have a creatinine clearance (CrCl) value greater than 80 mL/min, as calculated by the Cockcroft-Gault equation. * Participant must agree to practice an acceptable method of contraception throughout the clinical trial, as outlined in the protocol. Exclusion Criteria: * Unwilling or unable to comply with study procedures. * Use of any investigational drug (except Hezkue/Hezkue Turbo) within 30 days prior to dosing. * History of significant renal, hepatic, cardiovascular (including orthostatic hypotension), psychiatric, neoplastic, infectious disease, or diabetes mellitus. * Clinically significant abnormal lab results, vital signs, or ECGs. * Any hepatic impairment or abnormal liver function tests. * Positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody. * Clinically significant illness within 28 days prior t…